用abrocitinib成功治疗耐火性红皮肤炎:一个案例报告
Yuping Zhang1,2, Chen Li2, Chuanjian Lu1,3,4
1The Second Clinical Medical College of Guangzhou University of Chinese Medicine, Guangzhou, China.
Case reports in dermatology
|March 12, 2026
概括
阿布罗西提尼布在治疗对标准疗法无反应的严重红皮病方面表现有前途. 这种Janus激酶 (JAK) 抑制剂帮助一个患者实现显著改善,并停止使用葡萄糖皮质类药物,没有任何不良事件.
科学领域:
- 皮肤病学 皮肤病学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 红色皮肤是一种严重的皮肤疾病,对耐火病例的治疗选择有限.
- 像葡萄糖皮质激素,免疫抑制剂和生物药物等常规疗法通常是无效的.
研究的目的:
- 为了评估abrocitinib在耐火性红皮肤病患者的疗效和安全性.
- 评估abrocitinib作为治疗重症,耐治疗性红皮肤的替代治疗的潜力.
主要方法:
- 这里介绍了一个成年患者患有耐火性红皮皮质的病例报告.
- 阿布罗西替尼 (abrocitinib) 开始用于急性发作管理,并与逐渐减缓的葡萄糖皮质激素疗法一起使用.
主要成果:
- 患者经历了红血和相关症状的显著减少.
- 观察到头发重新生长,并成功停止使用葡萄糖皮质激素.
- 在6个月的随访期间,没有发现复发或严重不良事件.
结论:
- 阿布罗西替尼可能是对抗现有治疗方法的红色皮肤病的可行的治疗选择.
- 需要进一步的临床试验来证实abrocitinib在更大患者群体中的疗效和安全性.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
631
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
631
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
593
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
593
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
692
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
692

